

1 Tolerability of daily intermittent or continuous short-arm
2 centrifugation during 60-day 6° head down bed rest (AGBRESA
3 study)
4

5 Timo Frett¹, David Andrew Green^{2, 3, 4}, Edwin Mulder¹, Alexandra Noppe¹, Michael Arz¹,
6 Willi Pustowalow¹, Guido Petrat¹, Uwe Tegtbur⁵, Jens Jordan^{1, 6}

7
8 ¹ Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany

9 ² Space Medicine Team, European Astronaut Centre, European Space Agency,
10 Cologne, Germany

11 ³ KBRwyle GmbH, Cologne, Germany

12 ⁴ King's College London, London, UK

13 ⁵ Institutes of Sports Medicine, Hannover Medical School, Hannover, Germany

14 ⁶ Chair of Aerospace Medicine, University of Cologne, Cologne, Germany
15
16
17

18 Corresponding author:

19 Timo Frett

20 Institute of Aerospace Medicine

21 German Aerospace Center

22 Linder Hoehe

23 51147 Cologne, Germany

24 E-Mail: Timo.frett@dlr.de

25 Web: www.dlr.de/me
26

27 **ABSTRACT**

28 Artificial gravity through short-arm centrifugation has potential as a multi-system
29 countermeasure for deconditioning and cranial fluid shifts that may underlie ocular issues
30 in microgravity. However, the optimal short-arm centrifugation protocol that is effective
31 whilst remaining tolerable has yet to be determined.

32 Given that exposure to centrifugation is associated with presyncope and syncope and in
33 addition motion sickness an intermittent protocol has been suggested to be more
34 tolerable. Therefore, we assessed cardiovascular loading and subjective tolerability of
35 daily short arm centrifugation with either an intermittent or a continuous protocol during
36 long-term head-down bed rest as model for microgravity exposure in a mixed sex cohort.

37 During the Artificial Gravity Bed Rest with European Space Agency (AGBRESA) 60 day
38 6° head down tilt bed rest study we compared the tolerability of daily +1 Gz exposure at
39 the center of mass centrifugation, either performed continuously for 30 minutes, or
40 intermittently (6 x 5 minutes). Heart rate and blood pressure were assessed daily during
41 centrifugation along with post motion sickness scoring and rate of perceived exertion.

42 During bed rest, 16 subjects (6 women, 10 men), underwent 960 centrifuge runs in total.
43 Ten centrifuge runs had to be terminated prematurely, 8 continuous runs and 2
44 intermittent runs, mostly due to pre-syncopal symptoms and not motion sickness. All
45 subjects were, however, able to resume centrifuge training on subsequent days.

46 We conclude that both continuous and intermittent short-arm centrifugation protocols
47 providing artificial gravity equivalent to +1 Gz at the center of mass is tolerable in terms of
48 cardiovascular loading and motion sickness during long-term head down tilt bed rest.
49 However, intermittent centrifugation appears marginally better tolerated, albeit differences
50 appear minor.

51
52
53

INTRODUCTION

54 Long term space missions elicit multi-system deconditioning including reduced skeletal
55 muscle strength [1], bone mineral density [2], and central blood volume [3-5]. Moreover,
56 sustained cephalad fluid shifts appear to negatively affect ocular health and brain
57 structure, leading to the so-called space associated neuro-ocular syndrome [6, 7].
58 Furthermore, returning astronauts may experience reduced aerobic capacity [8], and
59 pre-syncopal symptoms indicative of poorer orthostatic tolerance [9]. In an attempt to
60 counter deconditioning on the International Space Station, integrated resistance and
61 aerobic training is prescribed using a number of dedicated devices [10].

62 Crewmembers train 6-7 days per week with 6-7 resistance and 4-7 cardiovascular
63 sessions per week [11, 12]. Daily training requires approximately 2.5 hours per
64 crewmember including the training, rest periods, and equipment setup, stowage and
65 cleaning. Despite the substantial investment of time, resource and effort this approach is
66 not entirely effective in mitigating musculoskeletal [13], nor aerobic [5, 14]
67 deconditioning, hence physical rehabilitation is required following return to Earth.
68 Moreover, no effective countermeasures against space associated neuro-ocular
69 syndrome currently exist. Thus more effective and ideally more efficient
70 countermeasures are required for future missions to the Moon, and beyond [15].

71 Artificial gravity through axial acceleration generated by short-arm human
72 provides musculoskeletal loading via the generation of ground reaction forces and an
73 orthostatic challenge through a hydrostatic pressure gradient both of which are absent in
74 microgravity. Indeed, short-arm human centrifugation may attenuate bone, muscle, and
75 cardiovascular deconditioning [16] induced by 6° head-down bed rest. For instance, in

76 short term (5 day) bed rest, an established terrestrial model of cephalad fluid shifts and
77 space-associated deconditioning [17]) studies, daily 30 minutes centrifugation with at
78 least 1 g at the center of mass resulted in no change in postural muscle strength with
79 good tolerability [18, 19]. Furthermore, exposure to artificial gravity appeared to provide
80 protection against post-bed rest orthostatic intolerance [20-22]. The primary objective of
81 the AGBRESA bed rest study is to compare the protective effects of one single daily
82 bout (30 min) versus multiple daily bouts of AG (6 x 5 min) on physiological functions
83 that are affected by simulated weightlessness during 60 days of bed rest.

84 However, exposure to exaggerated hydrostatic pressure gravitational gradients
85 induced by centrifugation can elicit presyncopal symptoms or syncope [20, 23, 24].
86 Furthermore, head movements within a rotating environment are associated with motion
87 sickness symptoms [25]. Yet, to be acceptable as an integrative spaceflight
88 countermeasure, a form of repeated exposure to artificial gravity needs to be tolerable
89 over a long duration mission for both males and females as a number of recent studies
90 have observed sex differences in autonomic cardiovascular control during exposure to
91 orthostatic stress [23, 26, 27].

92 Thus, the aim of our study were to assess the tolerability of daily 30 minute
93 intermittent, or continuous short-arm centrifugation with 1 g at center of mass during 60
94 days (6°) head-down bedrest in a mixed sex cohort.

95

96 **METHODS**

97 **Study subjects.** This study is part of the NASA/ESA/DLR 60-day 6° head down
98 bed rest study 'Artificial Gravity Bed Rest with European Space Agency' (AGBRESA)
99 that was conducted from March until December 2019 at the :envihab facility of the

100 Institute of Aerospace Medicine of the German Aerospace Center (DLR) in Cologne,
101 Germany. The study enrolled 24 healthy individuals (16 men, 8 women), who had been
102 submitted to detailed medical and psychological screening having provided written
103 informed consent. The study was approved by the North Rhine Medical Association
104 (2018143 vote from 17.08.2018).

105 **Protocol.** Following a 14-day baseline data collection period, study subjects
106 entered 60 days of strict 6° head-down bed rest. At the end of the baseline data collection
107 phase, participants were pseudo-randomly distributed into 3 groups: a control group with
108 no centrifugation, an intermittent centrifugation group, and a continuous centrifugation
109 group. The intermittent centrifugation group underwent daily 6x5 minutes centrifugation
110 with 3 minutes breaks between runs (Figure 1: Left Panel). The continuous centrifugation
111 group underwent a single daily 30 minute centrifugation run (Figure 1: Right Panel).

112 All centrifugation was performed using the :envihab short-arm human centrifuge
113 with participants exposed to +1 Gz at their center of mass (CoM) and thus approximately
114 +2 Gz at foot level. Rotational speed of the centrifuge was calculated individually based
115 upon each subject's anthropometry to determine center of mass (ratio center of mass to
116 body height 56% for male/ 54% for female). During ramp up/down phases,
117 (de)acceleration did not exceed 5° s⁻² to reduce the risk of vestibular-induced tumbling
118 sensations. All subjects underwent two centrifuge familiarization sessions prior to bed rest
119 at the same +Gz level as the main study with an intermittent profile of two 5 minute
120 periods separated by a 3 minute break.

121 Head restraints were not provided, but participants were instructed to keep their
122 body and head still throughout the centrifugation as much as possible. To assist in
123 maintaining consciousness and limit pre-syncopal symptoms, subjects were trained, prior

124 to the bed rest campaign, in the performance of voluntary isometric calf muscle pump
125 contractions along with (the trunk and gluteal muscles) to promote venous return [28].
126 However, subjects were instructed to contract only when experiencing significant (pre-
127 syncopal) symptoms such as dizziness or blurred vision.

128 **Cardiovascular monitoring.** During centrifugation, heart rate was continuously
129 recorded via a five lead electrocardiogram in addition to periodic brachial blood pressure
130 (Philips IntelliVue® MP2). In the intermittent centrifugation group, blood pressure was
131 recorded 2 minutes after each plateau (+1 Gz at center of mass), and in the continuous
132 centrifugation group 2 minutes after the plateau was achieved and every 5 minutes
133 thereafter. Mean heart rate, systolic and diastolic blood pressure were calculated for each
134 first measurement intervals during centrifugation on bed rest days 1, 30 and 60 and
135 compared between intervention groups.

136 Documentation of all adverse events including premature stops, pre-syncopal signs
137 or cardiac dysrhythmias was performed to facilitate evaluation of tolerability.

138 **Subjective tolerability assessment.** General motion sickness susceptibility
139 questionnaire short-form (MSSQ-SF) [29] was determined prior to the head down tilt bed
140 rest including both childhood (MSA) and adulthood (MSB) sub-scores. In both centrifuge
141 groups, Subjective Motion Sickness Ratings (MS: 0 “I am feeling fine” to 20 “I am about to
142 vomit”) [30] and rate of perceived exertion (RPE: 6 “No exertion at all” to 20 “Maximal
143 exertion”) [31] directly after every centrifuge run during bed rest were recorded.
144 Furthermore, Motion Sickness Assessment Questionnaire (MSAQ), Positive and Negative
145 Affect Schedule (PANAS) and Epworth Sleepiness Scale (ESS) were obtained on a
146 weekly basis directly before, and after centrifugation. MSAQ was employed to determine
147 (1 to 9 max) various dimensions (e.g. gastrointestinal) of motion sickness [32]. PANAS

148 was used to assess the effect of centrifugation upon mood. Participants rated each item
149 on a Likert scale from 1 “not at all” to 5 “very much”. The ESS (via rating from 0 (non-) to 3
150 “high chance of dozing” in 8 contexts) was used to evaluate “drowsiness” since it is a
151 cardinal symptom of motion sickness [33-35]. Furthermore, whenever a centrifuge run
152 was terminated prematurely, the reason was recorded.

153 **Statistical analysis.** Generalized linear mixed models with auto-regressive error
154 AR(1) were used to determine if there was an effect of bed rest (time effect) and
155 intervention (intermittent vs. continuous group). Mean values were reported with standard
156 deviation. All residual plots were evaluated using Kolmogorov-Smirnov with none
157 displaying large deviations from normality. All statistical tests were conducted using IBM
158 SPSS version 21 (IBM Corp., USA) with $\alpha < 0.05$ indicating statistical significance.

159

160 **RESULTS**

161 The average spin rate required to generate +1 Gz at the center of mass was 30.5
162 ± 1.0 rpm with radii within 1729 – 2113 mm at the foot plate. The 16 participants
163 allocated to the two centrifuge groups comprised 10 men and 6 women (71.6 ± 7.4 kg, 33
164 ± 9.9 yrs, 173 ± 8.8 cm) who experienced 960 centrifuge runs in total.

165 No serious adverse medical events occurred. However, a total of 10 centrifuge
166 runs (1%, involving 6 different subjects) had to be terminated prematurely; eight runs in
167 the continuous group and two runs in the intermittent group (Figure 2). Of the 10
168 terminated runs, seven runs – five in the continuous group and two in the intermittent
169 group - had to be terminated due to pre-syncope signs or symptoms, including significant
170 drop of blood pressure, reporting of tunnel vision and/or lightheadedness. Only one
171 centrifuge run in the continuous group had to be stopped due to severe motion sickness

172 (subsequent MS score of 18/20). Two runs in the continuous group had to be terminated
173 prematurely due to pain resulting from a recent muscle biopsy procedure performed for a
174 different experiment within the bed rest campaign.

175 No clinically significant cardiac dysrhythmias were observed during centrifugation.
176 During continuous centrifugation, two participants demonstrated frequent isolated
177 premature ventricular complexes on 14 non-consecutive days between bed rest days 5
178 and 51. Two participants in the continuous group and one in the intermittent centrifugation
179 group exhibited occasional premature atrial complexes, but there was no apparent
180 increase in incidence over time. All subjects were, however, able to resume centrifuge
181 training on subsequent days after a termination.

182 Comparisons of the initial cardiovascular reactions after 2 minutes of centrifugation
183 on bed rest days 1, 30 and 60 revealed significant effects during bed rest for mean heart
184 rate. Mean heart rates were significantly affected by time for the continuous ($F = 14.950$, p
185 < 0.001 , $dfs = 14.073$) but not for the intermittent group during bed rest ($F = 1.558$, $p =$
186 0.242 , $dfs = 15.281$). Thus mean heart rate was numerically higher in the continuous
187 group on bed rest day 60 but not significant (continuous group: 100.5 ± 18.5 vs.
188 intermittent group: 86.9 ± 5.9 , $t(14) = -1.986$, $p = 0.67$) (Table 1). We observed no
189 significant differences in systolic and diastolic blood pressure.

190 Overall MSSQ scores were similar ($p = 0.211$) prior to bed rest with 3.5 ± 5.4 (MSA
191 1.9 ± 2.7 ; MSB 1.6 ± 2.7) for the intermittent centrifugation, 6.0 ± 3.7 (MSA 2.9 ± 2.4 ; MSB
192 3.1 ± 2.1) for the continuous centrifugation, and 4.7 ± 4.1 (MSA 2.8 ± 2.8 ; MSB 1.9 ± 3.0)
193 for the control group.

194 Daily motion sickness scores were significantly higher in the continuous
195 centrifugation group during bed rest ($F = 92.8$, $p = 0.001$, $dfs = 202.5$) with no effect of bed

196 rest time ($F = 0.268$, $p = 0.605$, $dfs = 217.2$) (Figure 3). Pairwise comparison revealed
197 higher motion sickness scores in the continuous (3.05 ± 0.11) compared to the intermittent
198 centrifugation group (1.58 ± 0.11) ($p = 0.001$).

199 No significant differences in RPE, MSAQ, PANAS or ESS scores were observed
200 during the bed rest phase neither in either nor between groups (Figure 4, Table 2).

201

202 **DISCUSSION**

203 We evaluated the tolerability of daily artificial gravity via short-arm centrifugation as a
204 potential countermeasure against deconditioning induced by 60 day bed rest provided
205 either as a single 30 min run or as 6x5 minute runs. Our main findings were that both
206 centrifuge interventions were well tolerated (in both males and females), with no serious
207 adverse events and <1% run termination due to pre-syncopal signs. Only a single run
208 was stopped due to motion sickness, with two terminated due to pain from an
209 experimental procedure from another protocol. All subjects were, however, able to
210 resume centrifuge training on subsequent days. Daily motion sickness scores were low,
211 but significantly higher in the continuous group across bed rest. MSAQ, PANAS or ESS
212 scores were low in both centrifugation groups with no difference between groups
213 indicative of good long-term tolerability.

214 Short-arm centrifugation induces an orthostatic stress on the cardiovascular
215 system that markedly differs from standing on Earth. While the body experiences 1 g
216 terrestrial gravity throughout with standing, the gravitational stimulus increases in a graded
217 fashion from the head towards the feet during short-arm centrifugation [1].

218 Yet, previous studies have not observed major differences in cardiovascular
219 regulation when standing and during short-arm centrifugation [36]. In our study, pre-

220 syncope occurred in only a few runs and we did not observe overt syncope. Pre-syncope
221 did occur slightly more frequently in the continuous centrifugation group, suggesting that
222 the breaks in the intermittent protocol may contribute to improved orthostatic tolerance
223 during centrifugation. However, in both groups the incidence was very low, potentially due
224 to the fact that subjects were permitted to perform isometric leg muscle pump exercises
225 when experiencing symptoms. In the absence of countermeasures, bed rest
226 deconditioning is associated with markedly reduced orthostatic tolerance [37].
227 Interestingly, we did not observe worsening tolerability of short-arm centrifugation over
228 time suggesting that daily artificial gravity may have maintained orthostatic tolerance but
229 this requires further evaluation including specific testing of orthostatic tolerance during bed
230 rest [19].

231 While we did not observe higher degree cardiac dysrhythmias during centrifugation,
232 frequent isolated premature ventricular complexes in two participants in the continuous
233 centrifugation group are noteworthy as long-arm centrifugation nor orthostatic stress
234 imposed by standing are associated with cardiac dysrhythmias in otherwise healthy
235 persons [38, 39]. Whether premature ventricular complexes were triggered by short-arm
236 centrifugation or other stresses resulting from the complex multi-experimental study
237 cannot be discerned. It is reassuring that orthostatic stress imposed by standing or long-
238 arm centrifugation rarely produces significant cardiac dysrhythmias in otherwise healthy
239 persons [38, 39]. While presyncope occurred slightly more frequently in the continuous
240 centrifugation group the incidence is too small to perform a comprehensive study on
241 intervention group effects. Premature termination of a centrifugation runs were also (albeit
242 rarely) caused by pain due to muscle biopsy from another experiment that were also

243 associated with higher perceived exertion ratings on bed rest days 6 and 55, corroborated
244 by subject comments documented by the attending physician.

245 As the objective of the present study was to expose subjects to +1 Gz at the center
246 of mass and approximately +2 Gz at the level of the feet, spin rates during centrifugation
247 were relatively high. During such spin rates head movements can exacerbate motion
248 sickness due to induced conflicts between acceleration (gravity) perception and other
249 sensory inputs [25, 40-42]. However, in our study these spin rates were well tolerated
250 even without physical head restraint or head cover to put subjects into darkness which is
251 commonly used. Remarkably, despite the fact that participants were requested, but not
252 physically prevented from moving the head, only a single centrifuge run was stopped due
253 to severe motion sickness symptoms. Indeed, daily ratings for motion sickness did not
254 indicate increases over time in discomfort due to centrifugation-induced cross-coupled
255 sensations.

256 Thus, this suggests that by limiting centrifugal acceleration to 5° s^{-2} the risk of
257 significant motion sickness is low, even in the intermittent group whom were exposed to
258 multiple acceleration and decelerations within each session. Thus, why higher (albeit not
259 high) motion sickness ratings were reported in the continuous group is unknown and
260 warrants further study – particularly as MSAQ scoring did not differ significantly between
261 groups. Potential limitations of our study are overestimation of questionnaire results as
262 direct comparison with the control group were not obtained due to the complexity of the
263 study. Although our results may be in accordance with other studies showing high levels
264 of vestibular adaption to high speed short radius rotations over time [12, 30, 43] that may
265 also underlie the low scores for PANAS negative affects – suggesting potentially good
266 long-term tolerability.

267 In conclusion short-arm centrifugation was well tolerated (in both males and
268 females) during 60-days of 6° head-down tilted bedrest. 30 minute intermittent
269 centrifugation appears to be slightly better tolerated compared to equivalent continuous
270 centrifugation indicated by lower motion sickness scores and fewer run terminations.
271 However, the differences were small and require further study in a mixed sex cohort
272 both as 'passive' countermeasures and potentially with concurrent exercise as this may
273 augment effectiveness against multi-systems de-conditioning.

274
275

276 **Data Availability**

277 The datasets generated from the study are available.

278
279 **Acknowledgement**

280 The authors would like to thank the DLR centrifuge team and DLR study team for their
281 support in the experiment. Further gratitude belongs to NASA and ESA for their
282 cooperation.

283

284 **Author contributions**

285 T.F., J.J., and D.G. wrote the manuscript, T.F., designed the research and analyzed the
286 data, T.F., A.N., M.A., W.P., G.P. performed the research, J.J., D.G. and U.T.
287 supervised the experiment.

288

289 **Funding**

290 The “Artificial Bed Rest study with European Space Agency” (ABRESA) study was
291 financed by NASA and ESA. Our experiments were included into the study conduction
292 and financed by the DLR Institute of Aerospace Medicine. KBRwyle GmbH provided
293 support in the form of salaries only for author D.G, but did not have any additional role in
294 the study design, data collection and analysis, decision to publish, or preparation of the
295 manuscript. The specific roles of these authors are articulated in the ‘author
296 contributions’ section.

297

298

299 **Disclosures**

300 None.

301

302

303

304 **Competing interests**

305 The authors declare no competing interests as KBRwyle GmbH had no role in the study
306 design. This does not alter our adherence to PLOS ONE policies on sharing data and
307 materials.

308

309 REFERENCES

- 310
- 311 1. Clément, G. and A. Buckley, *Artificial gravity*. Vol. 20. 2007: Springer Science &
312 Business Media.
 - 313 2. Lang, T., et al., *Towards human exploration of space: the THESEUS review*
314 *series on muscle and bone research priorities*. NPJ Microgravity, 2017. **3**: p. 8.
 - 315 3. Arnauld E. Nicogossian, R.S.W., Carolyn L. Huntoon, Charles R. Doarn, James D.
316 Polk, Victor S. Schneider, *Space Physiology and Medicine: From Evidence to*
317 *Practice*. 2016.
 - 318 4. Chang, D.G., et al., *Lumbar spine paraspinal muscle and intervertebral disc*
319 *height changes in astronauts after long-duration spaceflight on the International*
320 *Space Station*. Spine, 2016. **41**(24): p. 1917-1924.
 - 321 5. Moore, A.D., Jr., et al., *Peak exercise oxygen uptake during and following long-*
322 *duration spaceflight*. J Appl Physiol (1985), 2014. **117**(3): p. 231-8.
 - 323 6. Lee, A.G., et al., *Space flight-associated neuro-ocular syndrome (SANS)*. Eye,
324 2018. **32**(7): p. 1164-1167.
 - 325 7. Roberts, D.R., et al., *Effects of Spaceflight on Astronaut Brain Structure as*
326 *Indicated on MRI*. New England Journal of Medicine, 2017. **377**(18): p. 1746-
327 1753.
 - 328 8. Buckley Jr, J.C., et al., *Orthostatic intolerance after spaceflight*. Journal of Applied
329 Physiology, 1996. **81**(1): p. 7-18.
 - 330 9. Blaber, A.P., et al., *Impairment of cerebral blood flow regulation in astronauts with*
331 *post flight orthostatic intolerance*. Stroke, 2011. **42**: p. 1844 - 1850.
 - 332 10. Hackney, K.J., et al., *The Astronaut-Athlete: Optimizing Human Performance in*
333 *Space*. The Journal of Strength & Conditioning Research, 2015. **29**(12): p. 3531-
334 3545.
 - 335 11. Petersen, N., et al., *Exercise in space: the European Space Agency approach to*
336 *in-flight exercise countermeasures for long-duration missions on ISS*. Extreme
337 Physiology & Medicine, 2016. **5**: p. 9.
 - 338 12. Young, L.R., et al., *Artificial gravity: head movements during short-radius*
339 *centrifugation*. Acta Astronaut, 2001. **49**(3-10): p. 215-26.
 - 340 13. Lang, T., et al., *Towards human exploration of space: the THESEUS review*
341 *series on muscle and bone research priorities*. npj Microgravity, 2017. **3**(1): p. 8.
 - 342 14. Lee, S.M.C., et al., *Orthostatic Intolerance After ISS and Space Shuttle Missions*.
343 Aerospace Medicine and Human Performance, 2015. **86**(12): p. A54-A67.
 - 344 15. Scott, J.P.R., T. Weber, and D.A. Green, *Introduction to the Frontiers Research*
345 *Topic: Optimization of Exercise Countermeasures for Human Space Flight –*
346 *Lessons From Terrestrial Physiology and Operational Considerations*. Frontiers in
347 Physiology, 2019. **10**(173).
 - 348 16. Kaderka J, Y.L., Paloski WH, *A critical benefit analysis of artificial gravity as a*
349 *microgravity countermeasure*, in *Acta Astronautica*. 2010. p. 1090-1102.
 - 350 17. Hargens, A.R. and L. Vico, *Long-duration bed rest as an analog to microgravity*. J
351 Appl Physiol (1985), 2016. **120**(8): p. 891-903.
 - 352 18. Clement, G., et al., *Effects of five days of bed rest with intermittent centrifugation*
353 *on neurovestibular function*. J Musculoskelet Neuronal Interact, 2015. **15**(1): p.
354 60-8.

355 19. Clément, G., et al., *Centrifugation as a countermeasure during bed rest and dry*
356 *immersion: What has been learned?* Journal of musculoskeletal & neuronal
357 interactions, 2016. **16**(2): p. 84-91.

358 20. Iwase, S., et al., *Effects of graded load of artificial gravity on cardiovascular*
359 *functions in humans.* ENVIRONMENTAL MEDICINE-NAGOYA-, 2002. **46**(1/2): p.
360 29-32.

361 21. Goswami, N., et al., *Effects of individualized centrifugation training on orthostatic*
362 *tolerance in men and women.* PLoS One, 2015. **10**(5): p. e0125780.

363 22. Convertino, V.A., *Gender differences in autonomic functions associated with*
364 *blood pressure regulation.* American Journal of Physiology-Regulatory,
365 Integrative and Comparative Physiology, 1998. **275**(6): p. R1909-R1920.

366 23. Goswami, N., et al., *Effects of individualized centrifugation training on orthostatic*
367 *tolerance in men and women.* PLoS One, 2015. **10**(5): p. e0125780.

368 24. Evans, J.M., et al., *Centrifuge training increases presyncopal orthostatic tolerance*
369 *in ambulatory men.* Aviation, space, and environmental medicine, 2004. **75**(10):
370 p. 850-858.

371 25. Bertolini, G. and D. Straumann, *Moving in a Moving World: A Review on*
372 *Vestibular Motion Sickness.* Front Neurol, 2016. **7**: p. 14.

373 26. Evans, C.R., M.G. Medina, and A.M. Dwyer, *Telemedicine and telerobotics: from*
374 *science fiction to reality.* Updates Surg, 2018. **70**(3): p. 357-362.

375 27. Evans, J.M., et al., *Gender differences in autonomic cardiovascular regulation:*
376 *spectral, hormonal, and hemodynamic indexes.* J Appl Physiol (1985), 2001.
377 **91**(6): p. 2611-8.

378 28. Styf, J., *The venous pump of the human foot.* Clin Physiol, 1990. **10**(1): p. 77-84.

379 29. Golding, J.F., *Predicting individual differences in motion sickness susceptibility by*
380 *questionnaire.* Personality and Individual Differences, 2006. **41**(2): p. 237-248.

381 30. Young, L.R., et al., *Adaptation of the vestibulo-ocular reflex, subjective tilt, and*
382 *motion sickness to head movements during short-radius centrifugation.* J Vestib
383 Res, 2003. **13**(2-3): p. 65-77.

384 31. Borg, G., *Borg's perceived exertion and pain scales.* Borg's perceived exertion
385 and pain scales. 1998, Champaign, IL, US: Human Kinetics. viii, 104-viii, 104.

386 32. Gianaros, P.J., et al., *A Questionnaire for the Assessment of the Multiple*
387 *Dimensions of Motion Sickness.* Aviation, space, and environmental medicine,
388 2001. **72**(2): p. 115-119.

389 33. Graybiel, A. and J. Knepton, *Sopite syndrome: a sometimes sole manifestation of*
390 *motion sickness.* Aviat Space Environ Med, 1976. **47**(8): p. 873-82.

391 34. Lawson, B.D. and A.M. Mead, *The sopite syndrome revisited: drowsiness and*
392 *mood changes during real or apparent motion.* Acta Astronaut, 1998. **43**(3-6): p.
393 181-92.

394 35. Van Ombergen, A., B.D. Lawson, and F.L. Wuyts, *Motion sickness and sopite*
395 *syndrome associated with parabolic flights: a case report.* Int J Audiol, 2016.
396 **55**(3): p. 189-94.

397 36. Verma, A.K., et al., *Comparison of Autonomic Control of Blood Pressure During*
398 *Standing and Artificial Gravity Induced via Short-Arm Human Centrifuge.* Front
399 Physiol, 2018. **9**: p. 712.

400 37. Barbic, F., et al., *Effects of prolonged head-down bed rest on cardiac and*
401 *vascular baroreceptor modulation and orthostatic tolerance in healthy individuals.*
402 Frontiers in physiology, 2019. **10**: p. 1061.

- 403 38. Zawadzka-Bartczak, E.K. and L.H. Kopka, *Cardiac arrhythmias during aerobic*
404 *flight and its simulation on a centrifuge*. *Aviat Space Environ Med*, 2011. **82**(6): p.
405 599-603.
- 406 39. Suresh, R., et al., *Dysrhythmias in Laypersons During Centrifuge-Simulated*
407 *Suborbital Spaceflight*. *Aerosp Med Hum Perform*, 2017. **88**(11): p. 1008-1015.
- 408 40. Reason, J.T., *Motion sickness adaptation: a neural mismatch model*. *J R Soc*
409 *Med*, 1978. **71**(11): p. 819-29.
- 410 41. Reason, J.T. and J.J. Brand, *Motion sickness*. *Motion sickness*. 1975, Oxford,
411 England: Academic Press. vii, 310-vii, 310.
- 412 42. Bles, W., et al., *Motion sickness: only one provocative conflict?* *Brain Res Bull*,
413 1998. **47**(5): p. 481-7.
- 414 43. Newman, M.C., et al., *Motion sickness adaptation to Coriolis-inducing head*
415 *movements in a sustained G flight simulator*. *Aviat Space Environ Med*, 2013.
416 **84**(2): p. 104-9.
417
- 418

419 **FIGURE/TABLE LEGENDS**

420

421 Figure 1: Artificial Gravity was generated by centrifugation with +1Gz at Center of Mass
422 and approx. +2Gz at feet. Participants were randomly assigned to an intermittent
423 centrifugation group with 6 x 5 min centrifugation with 3 minute breaks (left side) and a
424 continuous group with 30 min centrifugation (right side).

425 Figure 2: Premature terminations of centrifuge sessions

426

427

428 Figure 3: Mean values with standard error of daily Motion Sickness (MS) rating
429 immediately following intermittent and continuous centrifugation during 60 day bed rest
430 in the intermittent and in the continuous centrifugation group.

431 Figure 4: Mean values with standard error of daily Rating of Perceived Exertion (RPE)
432 rating immediately following intermittent and continuous centrifugation during 60 day bed
433 rest in the intermittent and in the continuous centrifugation group.


434 Table 1: Comparison of mean values for heart rate, systolic and diastolic blood pressure
435 during the first 2 minutes of centrifugation at the beginning, middle and end of bed rest.

436


437 Table 2: Comparison of tolerability assessment (MSAQ, ESS, PANAS) of both centrifuge
438 intervention groups at the beginning, middle and end of bed rest.

439

440
441 Figure 1
442




460 Figure 2
461




462
463
464
465

466 Figure 3
467
468



469 Figure 4
470
471



472
473
474

475 Table 1
 476
 477

Bed rest phase						
	Begin		Middle		End	
	Intermittent group	Continuous group	Intermittent group	Continuous group	Intermittent group	Continuous group
Heart rate	80.3 ± 8.4	82.4 ± 14.9	86.3 ± 12.7	99.13 ± 18.6	86.9 ± 5.9	100.5 ± 18.5
Systolic blood pressure	119.3 ± 13.4	111.9 ± 41	122.3 ± 10.4	128.8 ± 7.5	130.5 ± 13.5	132.4 ± 11.1
Diastolic blood pressure	76.6 ± 5.9	80.8 ± 9.5	81.8 ± 4.5	84.3 ± 6.3	88.1 ± 8.2	93.8 ± 11.9

478
 479

480 Table 2

481

Bed rest phase						
	Begin		Middle		End	
	Intermittent group	Continuous group	Intermittent group	Continuous group	Intermittent group	Continuous group
MSAQ						
- Overall	21.96 ± 6.7	20.66 ± 3.7	16.32 ± 2.2	21.76 ± 6.1	19.71 ± 4.4	17.89 ± 2.5
- Gastrointestinal	21.18 ± 8.9	21.53 ± 4.5	12.50 ± 1.0	22.22 ± 7.6	14.93 ± 3.1	18.06 ± 3.4
- Central	18.06 ± 6.0	16.95 ± 3.3	13.89 ± 4.1	17.52 ± 5.7	16.11 ± 6.0	14.17 ± 2.5
- Peripheral	21.30 ± 5.5	25.92 ± 8.2	15.74 ± 0.6	28.39 ± 9.9	20.37 ± 3.7	18.05 ± 1.8
- Sopite-related	28.12 ± 7.9	20.49 ± 3.9	23.61 ± 4.1	21.61 ± 3.5	28.47 ± 6.4	22.22 ± 3.4
ESS	12.5 ± 1.3	12.25 ± 1.2	15.25 ± 2.3	12.56 ± 1.4	14.25 ± 2.0	13.36 ± 1.8
PANAS (Positive Affect)	23.88 ± 2.6	25.75 ± 2.7	24.5 ± 2.0	24.11 ± 2.0	24.50 ± 3.1	22.88 ± 3.2
PANAS (Negative Affect)	15.50 ± 1.6	13.63 ± 0.5	13.13 ± 0.4	14.44 ± 1.1	15.00 ± 1.2	14.25 ± 0.8

482

483

484

485 Supporting informations

486

487 AGBR_Quest_results: List of all results from questionnaires ESS, MSAQ and PANAS in
488 a comprehensive manner

489

490 Medical data: List of all medical data including heart rate and blood pressure pre and
491 post centrifugation as well as within first two minutes during centrifugation.

492

493 MS Scoring HDT: Recording of motion sickness questionnaires during 60 days of head
494 down tilt bed rest.

495

496 RPE Scoring HDT: Recording of perceived exertion questionnaires during 60 days of
497 head down tilt bed rest.